Arcutis Biotherapeutics (ARQT) Profit After Tax (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Profit After Tax of -$11.8 million for Q1 2026, up 53.3% year-over-year from -$7.7 million in Q1 2025, and down 135.12% quarter-over-quarter from $33.5 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Profit After Tax (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$11.8 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 53.3% year-over-year to -$11.8 million; the TTM figure through Mar 2026 stood at $13.3 million (down 74.51% YoY), while the FY2025 annual figure was -$37000.0, down 236.36% from the prior year.
- Profit After Tax for Q1 2026 stood at -$11.8 million, down from $33.5 million in the prior quarter.
- The five-year high for Profit After Tax was $128.7 million in Q4 2024, with the low at -$108.1 million in Q3 2022.
- The 5-year median for Profit After Tax is -$44.7 million (2023), against an average of -$32.0 million.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax plunged 89.63% in 2022, then jumped 796.01% in 2025.
- Arcutis Biotherapeutics' Profit After Tax stood at -$72.0 million in 2022, then increased by 6.71% to -$67.2 million in 2023, then jumped by 291.57% to $128.7 million in 2024, then sank by 73.97% to $33.5 million in 2025, then tumbled by 135.12% to -$11.8 million in 2026.
- Business Quant data shows ARQT's Profit After Tax at -$11.8 million in Q1 2026, $33.5 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 15.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.01 Mn |
| Mar 31, 2026 | -11.77 Mn |
| Dec 31, 2025 | 33.50 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | -15.89 Mn |
| Mar 31, 2025 | -25.19 Mn |
| Dec 31, 2024 | 128.71 Mn |
| Sep 30, 2024 | 827,000.00 |
| Jun 30, 2024 | -52.33 Mn |
| Mar 31, 2024 | -35.38 Mn |
| Dec 31, 2023 | -67.19 Mn |
| Sep 30, 2023 | -44.66 Mn |
| Jun 30, 2023 | -70.99 Mn |
| Mar 31, 2023 | -80.10 Mn |
| Dec 31, 2022 | -72.02 Mn |
| Sep 30, 2022 | -108.05 Mn |
| Jun 30, 2022 | -67.41 Mn |
| Mar 31, 2022 | -64.32 Mn |
| Dec 31, 2021 | -71.56 Mn |
| Sep 30, 2021 | -56.98 Mn |